Literature DB >> 21212938

Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings.

Susanne Graef1, Peter Schönknecht, Osama Sabri, Ulrich Hegerl.   

Abstract

RATIONALE: The cholinergic system has long been linked to cognitive processes. Two main classes of acetylcholine (ACh) receptors exist in the human brain, namely muscarinic and nicotinic receptors, of which several subtypes occur.
OBJECTIVES: This review seeks to provide an overview of previous findings on the influence of cholinergic receptor manipulations on cognition in animals and humans, with particular emphasis on the role of selected cholinergic receptor subtypes. Furthermore, the involvement of these receptor subtypes in the regulation of emotion and brain electrical activity as measured by electroencephalography (EEG) shall be addressed since these domains are considered to be important modulators of cognitive functioning.
RESULTS: In regard to cognition, the muscarinic receptor subtypes have been implicated mainly in memory functions, but have also been linked to attentional processes. The nicotinic α7 receptor subtype is involved in working memory, whereas the α4β2* subtype has been linked to tests of attention. Both muscarinic and nicotinic cholinergic mechanisms play a role in modulating brain electrical activity. Nicotinic receptors have been strongly associated with the modulation of depression and anxiety.
CONCLUSIONS: Cholinergic receptor manipulations have an effect on cognition, emotion, and brain electrical activity as measured by EEG. Changes in cognition can result from direct cholinergic receptor manipulation or from cholinergically induced changes in vigilance or affective state.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212938     DOI: 10.1007/s00213-010-2153-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  229 in total

1.  The relationship between depression and cognition.

Authors:  R Gallassi; A Morreale; P Pagni
Journal:  Arch Gerontol Geriatr Suppl       Date:  2001

Review 2.  Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties.

Authors:  Karin R Tietje; David J Anderson; R Scott Bitner; Eric A Blomme; Paul J Brackemeyer; Clark A Briggs; Kaitlin E Browman; Dagmar Bury; Peter Curzon; Karla U Drescher; Jennifer M Frost; Ryan M Fryer; Gerard B Fox; Jens Halvard Gronlien; Monika Håkerud; Earl J Gubbins; Sabine Halm; Richard Harris; Rosalind J Helfrich; Kathy L Kohlhaas; Devalina Law; John Malysz; Kennan C Marsh; Ruth L Martin; Michael D Meyer; Angela L Molesky; Arthur L Nikkel; Stephani Otte; Liping Pan; Pamela S Puttfarcken; Richard J Radek; Holly M Robb; Eva Spies; Kirsten Thorin-Hagene; Jeffrey F Waring; Hilde Ween; Hongyu Xu; Murali Gopalakrishnan; William H Bunnelle
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

3.  Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment.

Authors:  A Nordberg; H Lundqvist; P Hartvig; J Andersson; M Johansson; E Hellstrŏm-Lindahi; B Långström
Journal:  Dement Geriatr Cogn Disord       Date:  1997 Mar-Apr       Impact factor: 2.959

4.  Nicotinic mechanisms of memory: effects of acute local DHbetaE and MLA infusions in the basolateral amygdala.

Authors:  Nii A Addy; Aya Nakijama; Edward D Levin
Journal:  Brain Res Cogn Brain Res       Date:  2003-03

5.  Dose effects of triazolam and scopolamine on metamemory.

Authors:  Miriam Z Mintzer; Bethea A Kleykamp; Roland R Griffiths
Journal:  Exp Clin Psychopharmacol       Date:  2010-02       Impact factor: 3.157

6.  Effects of scopolamine on matching to sample paradigm and related tests in human subjects.

Authors:  G Koller; W Satzger; M Adam; M Wagner; N Kathmann; M Soyka; R Engel
Journal:  Neuropsychobiology       Date:  2003       Impact factor: 2.328

7.  Smoking behaviors across anxiety disorders.

Authors:  Randi E McCabe; Susan M Chudzik; Martin M Antony; Lisa Young; Richard P Swinson; Michael J Zolvensky
Journal:  J Anxiety Disord       Date:  2004

8.  Arousal, anxiety, and performance: a reexamination of the Inverted-U hypothesis.

Authors:  Shawn M Arent; Daniel M Landers
Journal:  Res Q Exerc Sport       Date:  2003-12       Impact factor: 2.500

9.  [Manic behavior as an autoregulatory attempt to stabilize vigilance].

Authors:  U Hegerl; S Olbrich; P Schönknecht; C Sander
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

10.  Decreased anxiety-like behavior in beta3 nicotinic receptor subunit knockout mice.

Authors:  T K Booker; Christopher M Butt; Jeanne M Wehner; Stephen F Heinemann; Allan C Collins
Journal:  Pharmacol Biochem Behav       Date:  2007-04-21       Impact factor: 3.533

View more
  28 in total

1.  The prominent role of stimulus processing: cholinergic function and dysfunction in cognition.

Authors:  Maura L Furey
Journal:  Curr Opin Neurol       Date:  2011-08       Impact factor: 5.710

2.  Glucose attenuates impairments in memory and CREB activation produced by an α4β2 but not an α7 nicotinic receptor antagonist.

Authors:  Ken A Morris; Sisi Li; Duat D Bui; Paul E Gold
Journal:  Neuropharmacology       Date:  2012-11-16       Impact factor: 5.250

3.  Transcutaneous Vagus Nerve Stimulation Modulates Default Mode Network in Major Depressive Disorder.

Authors:  Jiliang Fang; Peijing Rong; Yang Hong; Yangyang Fan; Jun Liu; Honghong Wang; Guolei Zhang; Xiaoyan Chen; Shan Shi; Liping Wang; Rupeng Liu; Jiwon Hwang; Zhengjie Li; Jing Tao; Yang Wang; Bing Zhu; Jian Kong
Journal:  Biol Psychiatry       Date:  2015-04-02       Impact factor: 13.382

Review 4.  Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Cezary Skobowiat; Blazej Zbytek; Radomir M Slominski; Jeffery D Steketee
Journal:  Adv Anat Embryol Cell Biol       Date:  2012       Impact factor: 1.231

5.  The effects of prenatal stress on alpha4 beta2 and alpha7 hippocampal nicotinic acetylcholine receptor levels in adult offspring.

Authors:  Kalynn M Schulz; Kristin M Andrud; Maria B Burke; Jennifer N Pearson; Alison D Kreisler; Karen E Stevens; Sherry Leonard; Catherine E Adams
Journal:  Dev Neurobiol       Date:  2013-09-17       Impact factor: 3.964

6.  State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.

Authors:  Robert W Gould; Michael T Nedelcovych; Xuewen Gong; Erica Tsai; Michael Bubser; Thomas M Bridges; Michael R Wood; Mark E Duggan; Nicholas J Brandon; John Dunlop; Michael W Wood; Magnus Ivarsson; Meredith J Noetzel; J Scott Daniels; Colleen M Niswender; Craig W Lindsley; P Jeffrey Conn; Carrie K Jones
Journal:  Neuropharmacology       Date:  2015-11-23       Impact factor: 5.250

7.  Methamidophos exposure during the early postnatal period of mice: immediate and late-emergent effects on the cholinergic and serotonergic systems and behavior.

Authors:  Carla S Lima; Ana C Dutra-Tavares; Fernanda Nunes; André L Nunes-Freitas; Anderson Ribeiro-Carvalho; Cláudio C Filgueiras; Alex C Manhães; Armando Meyer; Yael Abreu-Villaça
Journal:  Toxicol Sci       Date:  2013-04-17       Impact factor: 4.849

8.  Central cholinergic involvement in sequential behavior: impairments of performance by atropine in a serial multiple choice task for rats.

Authors:  Stephen B Fountain; James D Rowan; Michael O Wollan
Journal:  Neurobiol Learn Mem       Date:  2013-07-18       Impact factor: 2.877

9.  GRK5 deficiency leads to susceptibility to intermittent hypoxia-induced cognitive impairment.

Authors:  Prabhakar Singh; Wei Peng; Qiang Zhang; XueFeng Ding; William Z Suo
Journal:  Behav Brain Res       Date:  2016-01-08       Impact factor: 3.332

Review 10.  The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders.

Authors:  Maddalena Mereu; Antonello Bonci; Amy Hauck Newman; Gianluigi Tanda
Journal:  Psychopharmacology (Berl)       Date:  2013-08-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.